DOI: https://doi.org/10.14710/dmj.v14i2.48430

Renal Dose Adjustment Management for Herpes Zoster in Immunocompromised Patient with Renal Impairment: A Case Report and Literature Review

Hapsari Kinanti orcid scopus  -  Department of Dermatology, Venereology, and Esthetic, Dr Soetomo General Academic Hospital, Surabaya, Indonesia, Indonesia
*Hasnikmah Mappamasing  -  Department of Dermatology, Venereology, and Esthetic, Dr Soetomo General Academic Hospital, Surabaya, Indonesia, Indonesia
Trisiswati Indranarum  -  Department of Dermatology, Venereology, and Esthetic, Dr Soetomo General Academic Hospital, Surabaya, Indonesia, Indonesia
Medhi Denisa Alinda  -  Department of Dermatology, Venereology, and Esthetic, Dr Soetomo General Academic Hospital, Surabaya, Indonesia, Indonesia
Linda Astari  -  Department of Dermatology, Venereology, and Esthetic, Dr Soetomo General Academic Hospital, Surabaya, Indonesia, Indonesia
Afif Nurul Hidayati  -  Department of Dermatology, Venereology, and Esthetic, Dr Soetomo General Academic Hospital, Surabaya, Indonesia, Indonesia

Citation Format:
Abstract

 

 Background: Herpes zoster is a reactivation of varicella-zoster virus that is characterized by a painful dermatomal vesicle eruption. Herpes zoster can bring several burdens including a painful rash and complications such as herpetic neuralgia and other neurological disorder. Herpes zoster commonly affects persons with decreased immunity levels which can caused by several conditions including malignancy. Multiple myeloma is one of the haematological malignancies commonly associated with renal impairments. Acyclovir is excreted in an unchanged form through renal, thus in patients with renal impairment could decrease the excretion level and can increase the possibility of renal toxicity. Case Presentation: We present a case report of a 46-year-old herpes zoster patient with multiple myeloma and renal impairment. The renal dose adjustment for acyclovir was done in this patient becomes 800mg three times daily. One week after the administration of acyclovir this patient showed remarkable results, there was no new lesion was found. This patient resolved after 10 days of renal dose adjustment of oral acyclovir and continued the multiple myeloma treatment on day fourteen. Conclusion: The management of herpes zoster infection in a patient with multiple myeloma commonly accompanies with renal impairment thus the consideration of adjusting the dose for renal impaired condition is important to reduce the possibility of renal toxicity in concordance with maintaining its adequate dose to prevent the possibility of complication

Fulltext View|Download
Keywords: Herpes zoster; immunocompromised patient; renal dose adjustment; tropical infection; case report

Article Metrics:

Article Info
Section: Case Report
Language : EN
Recent articles
The Sleep Quality Cost of Work-Related Social Restriction Policy Amidst Covid-19 Pandemic The Effect of Serving Temperature of Black Tea (Camellia sinensis) on the Hardness of Nanohybrid Composite Resin Influence of Nutrition and Hygiene Education for Stunting Prevention to Support the Acceleration of SDG`s Management of an Oral Ranula in a HIV positive patient: Case report The Efficacy of 0.5 Gram NaCl Capsule in the Treatment of Umbilical Granuloma in Neonates: A Case Report Renal Dose Adjustment Management for Herpes Zoster in Immunocompromised Patient with Renal Impairment: A Case Report and Literature Review More recent articles
  1. San Martin P, Aunhachoke K, Batac MCF, et al. Systematic Literature Review of Herpes Zoster Disease Burden in Southeast Asia. Infect Dis Ther. 2023;12(6):1553-1578. doi: 10.1007/s40121-023-00822-0
  2. Chen J, Abrahamson PE, Ke Y, Ong CR, Parikh R, Shantakumar S. A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific. Hum Vaccin Immunother. 2024;20(1). doi: 10.1080/21645515.2024.2344983
  3. Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-Induced Renal Failure Clinical Course and Histology. Am J Med. 1988;84:1067-1071
  4. Perazella MA. Drug-induced renal failure: Update on new medications and unique mechanisms of nephrotoxicity. American Journal of the Medical Sciences. 2003;325(6):349-362. doi: 10.1097/00000441-200306000-00006
  5. Wibisono O. Acyclovir Dosing Adjustment in a Chronic Kidney Disease Patient with Continuous Ambulatory Peritoneal Dialysis.; 2020. https://www.researchgate.net/publication/346564266
  6. van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021;17(6):1714-1732. doi: 10.1080/21645515.2020.1847582
  7. Koshy E, Mengting L, Kumar H, Jianbo W. Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. Indian J Dermatol Venereol Leprol. 2018;84(3):251-262. doi: 10.4103/ijdvl.IJDVL_1021_16
  8. Díaz-Tejedor A, Lorenzo-Mohamed M, Puig N, et al. Immune system alterations in multiple myeloma: Molecular mechanisms and therapeutic strategies to reverse immunosuppression. Cancers (Basel). 2021;13(6):1-26. doi: 10.3390/cancers13061353
  9. Yildiz C, Ozsurekci Y, Gucer S, Cengiz AB, Topaloglu R. Acute kidney injury due to acyclovir. CEN Case Rep. 2013;2(1):38-40. doi: 10.1007/s13730-012-0035-0
  10. Fleischer R, Johnson M. Acyclovir nephrotoxicity: A case report highlighting the importance of prevention, detection, and treatment of acyclovir-induced nephropathy. Case Rep Med. 2010;2010. doi: 10.1155/2010/602783
  11. Htwe TH, Bergman S, Koirala J. Famciclovir substitution for patients with acyclovir-associated renal toxicity. Journal of Infection. 2008;57(3):266-268. doi: 10.1016/j.jinf.2008.06.008
  12. Ashley C, Dunleavy A, Cunningham J. Foreword by The Renal Drug Handbook The Ultimate Prescribing Guide for Renal Practitioners. 5th ed. CRC Press Taylor & Francis Group; 2019. http://www.copyright
  13. Parikh R, Spence O, Giannelos N, Kaan I. Herpes Zoster Recurrence: A Narrative Review of the Literature. Dermatol Ther (Heidelb). 2024;14(3):569-592. doi: 10.1007/s13555-024-01101-7
  14. Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses. 2022;14(2). doi: 10.3390/v14020192
  15. Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices-United States, 2022. Morbidity and Mortality Weekly Report. 2022;71(3). https://www.cdc.gov/shingles/vaccination/immunocompromised-adults

Last update:

No citation recorded.

Last update:

No citation recorded.